Southern Company, Georgia Power Environmental Affair’s team featured KCNT1 mom, Alex Wild, and her family’s quest to work with the foundation to raise money for research.

KCNT1 warrior Mom shares her story of searching for a diagnosis and how she is working with the Foundation to help advance research and develop new treatments.

ABC News/Channel 7Health Reporter, Denise Dador interviews two families in So Cal.

Roman and his family are featured on PA ahead of the big Million Dollar Bike Ride!

Parents can keep up-to-date on some of the top news and studies.

One of our KCNT1 warriors continues to spread the word about KCNT1 and the need for new treatments and funding for research.

Our parent ambassador, Catherine Holliday, is doing a great job creating awareness for KCNT1. Her family has been featured by numerous media outlets after Action Medical funded a drug repurposing screening in search for KCNT1 inhibitors. We hope to identify a top candidate from the screening to take to clinical trials soon.

We are grateful for the Arpin International Group and Arpin Strong for selecting our charity to support for the month of March. Arpin’s history of giving back to the community is commendable and we are honored to have been selected and supported by all the employees. The entire KCNT1 community says thank you!

Meet KCNT1 warrior, Paddy and his family.

World Pharma Today’s interview by Dhaval Patel, Executive Vice President and Chief Scientific Officer of UCB, a global biopharmaceutical company focused on the discovery and development of novel drugs (including KCNT1) and solutions that have the potential to transform people’s lives. We also go in-depth on how UCB has advanced the field of drug discovery through technological partnerships.

Thanks to the Barns of Freeling for hosting a fundraiser. Over 1,000 people came out to water and pick sunflowers and many made a donation to the KCNT1 Epilepsy Foundation. Thank you to 7News!

Synopsis of KCNT1 programs in 2022.

UCB, a global biopharmaceutical company (EURONEXT BRUSSELS: UCB), and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, today announced a strategic collaboration, based upon Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies.

Treatment of KCNT1 mutant mouse models show improvements in behavior and reduced seizures.